ImmusanT, Inc. will use Microtest Laboratories’ pharmaceutical manufacturing and testing services to prepare its Nexvax2® immunotherapeutic vaccine for expected upcoming clinical trials. In addition to aseptic fill/finish services, Microtest will provide a full range of testing services to ImmusanT supporting its drug product manufacture, including method transfer activities, complete final product release testing, storage, and stability.

ImmusanT recently raised $20 million in financing to advance the development of Nexvax2 for the treatment of celiac disease. The disease is an inherited autoimmune disorder that is triggered by the consumption of foods containing gluten, causing an immune response resulting in inflammation of the small intestine. The safety, tolerability, and bioactivity of Nexvax2 have been established in a Phase 1 clinical study.

“As a one-stop source of on-site pharmaceutical testing and manufacturing services, Microtest provides a fast, efficient, cost-effective — and risk-minimizing — alternative to subcontracting with a variety of providers at multiple locations,” said Alex Mello, director of project management, Microtest. “We deliver the flexibility, solutions, and problem-solving manufacturers must have to ensure the most expeditious release of their products.”

Microtest offers flexible, customizable aseptic processing and fill/finish services – and a full-range of pharmaceutical testing services – for biotechnology and pharmaceutical companies of all sizes conducting Phase 1, 2, or 3 clinical trials.

Source: Microtest Laboratories, Inc.